Joslin Diabetes Center Research | Diabetic Eye Disease

by Lloyd Paul Aiello, M.D., Ph.D. Associate Director, Beetham Eye Institute, Joslin Diabetes Center; Associate Professor of Ophthalmology, Harvard Medical School

About half of all people with diabetes eventually develop some problem with their eyes or vision. They are more likely than others to get cataracts or glaucoma. The most feared eye complication, however, is diabetic retinopathy, which is relatively common and potentially sight threatening. But theres a lot we can do to preserve vision, even for those with diabetic retinopathy.

People with diabetes can help preserve their visionas well as reduce many of the complications associated with diabetesby controlling their blood glucose, blood pressure and cholesterol and triglyceride (lipid) levels. Even if they do not yet have diabetic eye complications, they need to have routine lifelong eye checkups at least once a year to catch any problems that start to develop. These examinations are critical because a person with eye complications often does not experience any symptoms that indicate damage until its too late to undo the damage. The presence of eye disease usually requires more frequent eye examinations.

Dont Wait for Symptoms
Diabetic retinopathy occurs when the tiny blood vessels inside the retinathe tissue at the back of the eye that sends images to the brainbecome damaged. There are usually no symptoms at this early nonproliferative stage. Essentially all people with diabetes will eventually develop some changes in the retina, usually within 20 years of diabetes onset.

In two-thirds of cases, this type of retinopathy progresses to the proliferative stage, although research shows that intensive glucose and blood pressure control can delay the onset of disease and slow its progression. In the proliferative stage, the retina forms new vessels in an attempt to circumvent nonfunctioning blood vessels. These new vessels, however, are abnormal, fragile and bleed readily. If the condition is treated with laser photocoagulation when the abnormal vessels are in their early stages, severe vision loss can be prevented in about 95 percent of cases. The laser scars the retina, causing the vessels to regress, which prevents subsequent bleeding and pulling on the retina. Since the laser destroys some areas of the retina, there may be side effects of treatmentsuch as reduced side or night visionbut central vision is retained far better than if the patient receives no treatment at all.

Diabetic macular edema, however, is a different story. Diabetes can cause the retinal vessels to leak, leading to swelling of the retina. If this swelling occurs in the small area in the center of the retina called the macula, the condition is called macular edema. Vision can decline because this area of the retina is responsible for central vision. Laser treatment is also used for this condition but is less successful than when used for new vessels. Treatment reduces the chance of vision worsening by only half, and, even when successful, is usually not associated with improved vision.

Promising New Drugs
Clearly wed like to have better treatments or multiple therapeutic approaches to offer patients. Fortunately, there are potential new medical therapies in the pipeline. Its an exciting time because many of these new drugs have emerged from recent and very specific understandings of the cellular mechanisms that underlie diabetic eye problems. Whether any will have an effect on preserving vision, we dont yet know. We first need to find out if theyre effective and what side effects they may cause.

One approach that Ive been studying involves a PKC inhibitor, a substance that blocks the action of an enzyme called protein kinase C (PKC). My colleagues at Joslin Diabetes Center and I have learned that PKC becomes activated early in diabetes by high glucose levels. Together we found that PKC triggers blood vessel dysfunction and that VEGF (vascular endothelial growth factor), which is thought to signal the formation of the abnormal blood vessels, needs PKC activity to be effective.

So far, results have shown that PKC inhibitors (taken as a pill) do not seem to stop the progression from nonproliferative to proliferative retinopathy, but might help with macular edema and vision loss. If proven effective, such a treatment would offer a new option to address a condition for which our existing treatment is not effective for everyone. The results of large clinical trials will be completed within the next two years.

Other approaches now being tested include inhibitors of VEGF and other growth factors like Insulin-like Growth Factor-1(IGF-1), as well as steroids injected into the eye. For example, a product called Macugen blocks VEGF and, when injected into the eye, appears in early patient studies to reduce macular edema and improve vision. A new steroid formulation designed specifically for the eye is being investigated by the Diabetic Retinopathy Clinical Research Network in patients for its potential effect in reducing macular edema and actually improving vision.

These new treatments under investigation offer great hope, but results of careful studies are needed before we know if any will be truly helpful. Participation in well designed clinical trials is important for future care. As for current eye care, everyone with diabetes should get annual eye checks and keep blood glucose, blood pressure and cholesterol in good control.

This article first appeared in the March 28, 2005 issue of Time Magazine

Courtesy of Joslin Diabetes Center

Last Modified Date: November 28, 2012

All content on is created and reviewed in compliance with our editorial policy.

More on this Topic

No items are associated with this tag

Sign up for FREE dLife Newsletters

dLife Membership is FREE! Get exclusive access, free recipes, newsletters, savings, and much more! FPO

You are subscribed!
You are subscribed!
You are subscribed!
2660 Views 0 comments
by Brenda Bell
As I mentioned in an earlier post, one of the benefits that made it cost-effective for me to go with the real healthcare (HSA) plan rather than the phony (HRA) plan is that my company is now covering "preventative" medicines at $0 copay. The formulary for these, as stated by CVS/Caremark (my pharmacy benefits provider), covers all test strips, lancets, and control solutions. I dutifully get my doctor to write up prescriptions for all of my testing needs, submit...
  • Watch dLifeTV online now!

    Click here for more info